Genetic screening in sporadic ALS and FTD

Area of Science:

• Neuroscience
• Genetics
• Neurology

Background:

• Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) exhibit complex genetic underpinnings.
• Autosomal dominant mutations are identified in at least 10% of ALS and FTD patients.
• Family history ascertainment for these conditions is often unreliable.

Discussion:

• Symptomatic individuals with ALS/FTD often seek to understand the genetic basis of their disease.
• Patient autonomy includes the right not to know genetic test results.
• Despite the lack of definitive therapies, many newly diagnosed patients opt for genetic testing.

Key Insights:

• Genetic testing in ALS and FTD provides crucial information for patients and their families.
• The prevalence of autosomal dominant mutations underscores the importance of genetic counseling.
• Addressing the complexity of genetic inheritance is vital for patient care.

Outlook:

• Enhanced physician training is needed to manage the genetic complexity of ALS and FTD.
• Standardized guidelines for family history assessment in genetic neurological disorders are warranted.
• Integrating genetic counseling into routine care pathways will improve patient support and decision-making.